Policy conference 10 March 2026 Canada’s medication spending has been relatively low; may need to be reconsidered because of US “most-favored nation” pharma pricing policy
Gerry Jeffcott | 3Sixty Public Affairs | ABSTRACT – Background: Public discourse often frames innovative
Policy conference 10 March 2026
You are invited to join the Canadian Health Policy Institute (CHPI) and 3Sixty Public Affairs for an important, in‑person forum
Does Canada pay its fair share of the global cost of pharmaceutical innovation?
Brett J Skinner, PhD | CEO, CHPI; Editor, CHPJ | ABSTRACT – The global cost
The Economic Burden of Seasonal Influenza in Quebec: Updated Estimates and Policy Implications
Yanick Labrie, MA | Health Economist, Yanick Labrie Consultant Inc. | ABSTRACT –
Bulk purchasing for innovative pharmaceuticals – proceed with caution
Neil Palmer | Independent Consultant | ABSTRACT – The promise of substantial additional cost savings
Net direct expenditure on patented medicines by public drug plans in 10 Canadian provinces in 2023
Brett Skinner, PhD | CEO CHPI, Editor CHPJ | ABSTRACT – Canada’s federal, provincial, and
Documenting Long-Acting Reversible Contraceptive (LARC) Coverage Across Canada
Haylie Simmons, BSc; Nichole Austin, PhD; Daniel Dutton, PhD | Dalhousie University | ABSTRACT –